ECCO 2022

The potential of histology in Crohn´s disease and how AI will contribute

Is the continuation of combination therapy the key to success in CD?

Combination trials open a new door in IBD treatment

Light at the end of the Pouchitis track

Microbiota manipulation: Still a lot to learn

Combined endpoints as new therapy goals

The first combination therapy trial

Is stopping of therapy an option in CD?

FMT is not a promising option for UC patients

A new opportunity for proactive TDM disease control

Ustekinumab for fistulizing disease

How to deescalate treatment in CD?

When to withdraw therapy in crohn's disease?

SPARE study in ECCO 2022

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

FMT in UC - still far away from the success story

A negative control trial for FMT in UC

Proactive TDM

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

Combination of biologics - finally arrived in IBD!?

Will we improve the management of IBD by combining biologics?

The interleukin-17 conundrum

Combination of biologics

Filgotinib for fistulizing disease

Combination with different classes of drugs in moderate to severe UC

Is the speedity of the steroid tapering important during initiation of infliximab?

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

FMT ist kein vielversprechender Ansatz für UC-Patienten

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Una nuova opportunità per i TDM nel controllo proattivo di malattia

Kombination von Biologika - endlich bei IBD angekommen!?

מחקר SPARE ב ECCO 2022

Il primo trial di terapia biologica di combinazione

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Combinazione di biologici

Ist der Therapiestopp eine Option in CD?

Das Interleukin-17 Rätsel

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Un essai négatif sur la transplantation de microbiote dans la RCH

COVID-19: still a moving target!

Is combination therapy safe?

Which IBD patients have a higher risk of safety concerns?

Can we translate rheumatoid arthritis to ulcerative colitis?

Inflammatory bowel disease and cancer risk

A touch of the near future in IBD treatment

The heart is apparently safe with continuous Ozanimod treatment

Breastmilk is tuning IBD risk

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Muttermilch beeinflusst das IBD-Risiko

Uno sguardo al prossimo futuro nel trattamento delle IBD

Efficacy update on JAKis

The race is on IL-23 – exciting data for CD and UC

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

Mucosal healing: Will efficacy data translate into real world?

Vedolizumab: promising data for pouchitis and IBD in children

Vedolizumab is effective in chronic pouchitis after IPAA for UC

Great news on pouchitis treatment - vedolizumab effective

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

New opportunity in pouchitis treatment

Selective IL-23 blockade

Anti-IL-23 - a turning point?

Upadacitinib - will it be the game changer in UC?

JAK inhibition

New ways of treatment

Guselkumab as maintenace treatment in Crohn's Disease

Anti-IL-23 - eine Zeitenwende?

Nuevos caminos en el tratamiento

Una nuova opportunità nel trattamemto della pouchite

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

Upadacitinib - nowy lek, duże nadzieje

Guselkumab come terapia di mantenimento

JAK-Inhibition

Selektive IL-23 Blockade

Natural history of anal ulcerations in pediatric-onset CD

Histological findings in mirikizumab treatment

New therapeutic goals in UC

Patient relevant outcomes also show efficacy of upadacitinib in UC

New therapy goals: urgency and disease clearance

New goals for IBD

Disease control is possible!

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Disease Control ist möglich!

Urgency und Disease Clearance

Nuevas objetivos en las EII

COVID-19 in patients with IBD stratified acc. to therapy

The efficacy of COVID-19 vaccines in IBD - what's new?

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Ultrasound as a predictor of treatment response

Point of Care Testing / AI / Telemedicine

Ultraschall als Prädiktor des Therapieansprechens

Digitale Tools, KI und Telemedizin

ECCO guidelines on pregnancy

Spanish women leading contribution to ECCO 2022

ECCO Richtlijnen zwangerschap

Las mujeres lideran la contribución española a la ECCO 2022